Przejdź do treściFracture nonunion is usually analysed in terms of mechanical stability, blood supply, infection, bone quality and systemic patient factors. A study published on 2 September 2026 in Science Translational Medicine adds a compelling immunological component: sustained neutrophil extracellular traps (NETs) may actively impair bone regeneration.
Why is this study clinically interesting?
NETs are structures released by neutrophils in response to tissue injury and infection. During acute trauma they are part of the normal inflammatory response. The study suggests, however, that the important issue is not simply whether NETs appear at a fracture site, but how long they persist. A short-lived response may form part of physiological healing, whereas prolonged activation may become detrimental.
The study is particularly interesting because it goes beyond a simple association. It combines observations in humans with mechanistic experiments in animal models and identifies a specific biological pathway linking persistent inflammation with impaired vascularisation of the fracture callus.
Study question and methodology
The investigators asked whether excessive and sustained NET formation could be causally related to fracture nonunion and whether suppressing this process might improve bone regeneration.
The study used mouse models with genetic alterations affecting NET formation or clearance, pharmacological inhibition of selected components of the pathway, and assessment of biomarkers in patients with normally healing fractures and in patients with nonunion. Particular attention was paid to type H vessels, which are involved in coupling angiogenesis with osteogenesis within the fracture callus.
Key findings
Bone injury produced a rapid increase in NET formation in both mice and humans. In normal healing, however, this response was transient.
- Genetically impaired NET clearance caused by combined deficiency of DNase1 and DNase1-like-3 initially favoured callus mineralisation, but later led to persistent NETs, impaired regeneration and more frequent nonunion.
- Additional deletion of PAD4, an enzyme important for NET formation, improved bone regeneration and reduced nonunion in the experimental model.
- Persistent NETs increased activation of the cGAS-STING pathway and reduced formation of type H vessels within the callus.
- Pharmacological inhibition of cGAS-STING restored type H vessel formation and improved healing in the relevant animal model.
- In patients with normal healing, serum NET markers declined over time. In nonunion, they remained elevated and were accompanied by greater accumulation of NETs and STING within the callus.
- In preclinical models, both the PAD4 inhibitor GSK484 and dornase alfa, a recombinant DNase I that enhances NET clearance, accelerated bone repair and reduced nonunion.
Clinical interpretation for an orthopaedic surgeon
One of the most important messages is that the inflammatory response after fracture is strongly time-dependent. The conclusion is not simply that “less inflammation means better healing”. Early neutrophil activity is part of normal fracture repair; the problem appears when mechanisms that should resolve that response fail.
A second important finding is the proposed connection between persistent immune activation and impaired angiogenesis. Type H vessels are associated with areas of active osteogenesis, so their loss provides a biologically plausible explanation for how abnormally prolonged neutrophil activation could translate into poorer bone regeneration.
For trauma surgeons, the work is also interesting because it may eventually support biological risk stratification. At present, nonunion risk is assessed mainly from the injury pattern, mechanical stability, soft-tissue condition, vascularity, infection and patient-related factors. Markers of sustained NET activity might one day complement these variables, but clinical use remains a distant prospect.
Limitations
The principal limitation is fundamental: the therapeutic interventions were evaluated preclinically. The human data show an association between sustained NET markers and nonunion, but they do not provide randomised evidence that inhibiting NETs in patients improves fracture healing.
Genetic models with impaired NET clearance deliberately create an exaggerated biological phenotype and may not reflect the most common causes of nonunion in routine trauma practice. The optimal timing, dose and duration of any therapy directed against NETs are also unknown. This matters because suppressing a normal inflammatory response too early or too strongly could theoretically have the opposite effect.
It is also unclear whether the mechanism will have similar importance across different fracture settings, including high-energy injuries, open fractures, infected fractures, osteoporotic bone or substantial mechanical instability.
What may change in practice—and what the study does not prove
At present, this study does not justify using dornase alfa, PAD4 inhibitors or cGAS-STING inhibitors to treat fracture nonunion. There are no clinical data defining efficacy, safety or a treatment regimen for orthopaedic patients.
The work does, however, change the biological framework in which nonunion can be considered. It describes a coherent sequence: sustained NETs → cGAS-STING activation → impaired type H vessel formation → poorer bone regeneration. If this is confirmed prospectively in humans, it could lead both to a new risk biomarker and to a new class of adjunctive therapies aimed at fracture healing.
A particularly valuable next step would be clinical research testing whether NET biomarker profiles can distinguish, early in the course of healing, fractures likely to unite normally from those at risk of nonunion. Controlled interventional trials would logically come later.
Back to: Trauma — Literature for Clinicians
Reference
Xie W, Albertsen L-C, Eis-Janzyk G, et al. Sustained neutrophil extracellular traps cause fracture nonunion. Science Translational Medicine. 2026;18(865):eadx9869. DOI: 10.1126/scitranslmed.adx9869. PubMed PMID: 42685150.
Content prepared by: Tomasz Poboży - orthopaedic surgeon.